ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Pfizer signs with Croda for vaccine excipients

by Rick Mullin
November 14, 2020 | APPEARED IN VOLUME 98, ISSUE 44

 

Croda International has signed a 5-year contract to supply lipid-based excipients to Pfizer for production of the drugmaker’s messenger RNA–based COVID-19 vaccine candidate. The inactive ingredients will be made by Avanti Polar Lipids, a high-purity lipids firm that Croda acquired earlier this year. The up-to-$100 million contract specifies that Croda will provide four excipients for the first 3 years of the agreement. The drug services firms Lonza and CordenPharma earlier landed lipid supply deals with Moderna, another front-runner in COVID-19 vaccines.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment